45 years ago GSK introduced the first short-acting β-2 agonist (salbutamol) and has since contributed to the treatment of chronic respiratory diseases such as bronchial asthma and chronic obstructive pulmonary disease (COPD). Most recently, GSK introduced two inhaled, 24-hour effective combination preparations consisting of muscarinic receptor antagonist and β-2 agonist (umeclidinium / vilanterol) and an inhaled corticosteroid and β-2 agonist (fluticasone furoate / vilanterol).
GSK also supports doctors and patients with services. www.PneumoWissen.de provides expert groups with current information on chronic respiratory diseases and, for example, integrates this into medical practice with video interviews by experts. In addition, webinars are offered for advanced training. This can be accessed on the go in the PneumoDoc app for iOS and Android, which supports doctor-patient discussions. GSK also offers various apps such as the AsthmaApp for patients. (DE / RESP / 0214/14 (1); 09.2015).
Source: GlaxoSmithKline GmbH & Co . KG, www.glaxosmithkline.de